Tipifarnib in the treatment of acute myeloid leukemia

Abstract

Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.

Keywords:

• tipifarnib
• farnesyltransferase inhibitor
• acute myeloid leukemia
• prognosis
• targeted therapy

Introduction

The outcome of therapy for acute myeloid leukemia (AML) has improved over the recent years, mainly in patients of younger age. However, the challenges in this area have remained considerable. AML is primarily a disease of the elderly and this patient population has a very poor prognosis, which is attributed to having disease that is inherently more resistant to current standard cytotoxic agents in relationship with acquired genetic characteristics of the leukemia, and/or relatively poor tolerance of these agents because of comorbidity and reduced tolerance of adverse effects. The unmet therapeutic need is therefore greatest among patients with AML of older age, in whom response rates are comparatively low (50% for those older than 60 years old), relapse rates are exceedingly high (more than 85%), and long-term survival rates are less than 10% (Löwenberg et al 1999; Rowe 2000).

The traditional chemotherapeutic approach to the patient with AML has been based on treatment with a combination of an anthracycline (or anthracenedione) with cytarabine. New drugs are currently in early clinical development with the aim of circumventing chemotherapy resistance. Biological insight into the mechanisms of defective molecular pathways in malignant cells has resulted in the identification of novel targets for drug development. Farnesyltransferase inhibitors (FTIs) represent a new class of signaling inhibitors that may inhibit critical growth and survival signals. These agents are competitive inhibitors of intracellular farnesyl protein transferase (FTase), an enzyme that catalyzes the transfer of a farnesyl moiety to the cysteine terminal residue of a substrate protein. A host of intracellular proteins are substrates for prenylation via Ftase. Interrupting the normal prenylation process of these substrate proteins has been shown useful for inhibiting cellular events that are governed by them (End 1999).

Four main approaches to blocking FTase have been designed: (i) competition with the farnesyl pyrophosphate (FPP) group using synthetic analogs, (ii) competition with the target protein or its CAAX binding site or both using peptides (peptidomimetics), (iii) competition with FPP and CAAX using analogs that combine features of both the FPP analogs and peptidomimetics, and (iv) competition with protein/CAAX using nonpeptide analogs (Rowansky et al 1999).

At least six FTIs have been tested in clinical trials, including BMS-214662 (Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com), L778123 (Merck and Co., Inc., Whitehouse Station, NJ, http://www.merck.com), lonafarnib (experimental name, SCH66336; Sarasar™; Schering-Plough Corporation, Kenilworth, NJ, http://www.sch-plough.com), FTI-277 (Calbiochem, EMD Bio-Sciences, San Diego, http://www.emdbiosciences.com), L744832 (Biomol International L.P., Plymouth Meeting, PA, http://www.biomol.com), and tipifarnib (experimental name, R115777; Zarnestra®; Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.orthobiotech.com), which is the most advanced FTI in clinical development (Brunner et al 2003).

This review outlines the characteristics of tipifarnib and its potential mechanisms of action, and describes the early results with this FTI in the treatment of AML.

Tipifarnib

Tipifarnib belongs to the nonpeptidomimetic FTIs. It is a 4,6-disubstituted-1-methylquinolin-2-one derivative that was obtained by optimization of a quinolone lead identified from compound library screening (Venet et al 2003) (Figure 1). Tipifarnib is synthesized by the condensation of the anion of 1-methylimidazole with a 6-(4-chlorobenzoyl) quinolone derivative, followed by dehydration. The quinolone intermediate was prepared in four steps by cyclization of N-phenyl-3-(3-chlorophenyl)-2-propenamide, acylation, oxidation and N-methylation. Tipifarnib was identified from Janssen’s ketoconazole and retinoic acid catabolism programs as a key structural feature into Ras prenylation process. Tipifarnib is a potent inhibitor of FTase in vitro and is orally active in a variety of animal models (End et al 2001). Tipifarnib was the first FTI tested in a clinical trial. It is reasonably well tolerated in man and requires twice-daily dosing to obtain effective plasma concentrations (Kurzrock et al 2004). Phase I studies showed that myelosuppression and neurotoxicity were dose-limiting toxicities. Gastrointestinal toxicities and fatigue were observed as well (Zujewski et al 2000; Crul et al 2002).

Figure 1 Structure of tipifarnib: R115777(R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolone. Tipifarnib is a farnesyltransferase inhibitor developed by Johnson & Johnson Pharmaceutical Research and Development LLC. It is a nonpeptidomimetic oral quinolone analog of imidazole-containing heterocyclic compounds. It competitively inhibits the CAAX binding site of farnesyl transferase. The imidazole group is the central pharmacophore and the imidazole may interact with the coordination structure of the zinc catalytic site.

Possible mechanisms of tipifarnib biological activity

FTIs were initially developed to specifically inhibit the activity of oncogenic ras in tumor cells by inhibiting the farnesylation of Ras. Evidence pointing to the importance of ras in myeloid leukemogenesis emanates from an in vivo model, in which irradiated mice, reconstituted with bone marrow transfected with activated N-ras, developed AML and myelodysplastic syndrome (Mackenzie et al 1999). At present, the mechanisms behind the anti-tumorigenic effects of FTIs appear complex. The role of ras inhibition in the antitumor activity of tipifarnib is a topic of debate, and other farnesylated targets have been identified.

The Ras protein

The family of ras genes consists of three functional genes, H-ras, K-ras, and N-ras. These genes are highly homologous and encode for four 21-kDa proteins: H-Ras, the splice variants Ki4A-Ras and Ki4B-Ras, and N-Ras, respectively. The N-ras gene is predominantly mutated in AML (30%) (Bos 1989).

Ras proteins are GTPases that play a central role in growth signal transduction pathways. Following isoprenylation in the cytosol, the Ras protein migrates to the cell membrane, where it is capable of activating downstream signaling events (End et al 1999; Khosravi-Far et al 1992; Cox et al 2001). Ras proteins contain 188 or 189 amino acids and exhibit high sequence homology, with the first 86 amino acids being identical, the next 78 having 79% homology, and the following 25 amino acids being highly variable. The final four amino acids play an important role in specifying subcellular localization of the Ras protein. All Ras proteins have a specific amino acid sequence motif at the COOH-terminal region, commonly referred to as the CAAX box, in which C represents a cysteine residue; AA represent aliphatic amino acids, usually valine, leucine, or isoleucine; and X is either methionine or serine. The membrane-targeting domain contains cysteine palmitoylation sites in H-Ras, N-Ras, and K-Ras4A or a polylysine domain in K-Ras4B. Palmitoylation or the presence of a polybasic domain is essential for efficient transportation to the plasma membrane. The transfer of a farnesyl group is mediated by the enzyme FTase, whereas transfer of a geranyl group is mediated by geranylgeranyl transferase (Figure 2). Ras protein isoforms differ in their affinity for specific isoprenyl groups. K-Ras is a higher affinity substrate for Ftase than H-Ras (Zhang et al 1997). Both N-Ras and K-Ras, but not H-Ras, are weak substrates for GGTase-1. In cell culture, FTIs prevent H-Ras farnesylation. In contrast K- and N-Ras are alternatively prenylated by GGTase-1 in FTI-treated cells (Whyte et al 1997). While membrane bound and upon binding an active deoxyguanosine triphosphate (GTP), Ras transduces the signal to various effector proteins (Figure 3). Subsequently, it becomes inactivated through conversion of GTP to an inactive guanosine diphosphate (GDP) by an intrinsic GTPase (Boguski and McCormick 1993). A point mutation in codon 12, 13, or 61 of the ras gene leads to insensitivity of Ras to the GTPase-activating protein (GAP) and a significantly lower GTPase activity, resulting in deranged or aberrant signal transduction (Lowy and Willumsen 1993).

Figure 2 Ftase catalyses the farnesylation step by recognizing the CAAX motif of the Ras C-terminus and transferring a 15-carbon farnesyl isoprenoid from farnesyl diphosphate to form a thioether bond with the Ras cysteine. In another principal prenylation reaction, protein geranylgeranyl transferases transfer either one or two 20-carbon geranylgeranyl isoprenoids from geranylgeranyl diphosphate to proteins (Rowinski et al 1999).

Figure 3 Ras processing and targeting to the plasma membrane. The cytosolic FTase catalyzes the covalent addition of farnesol from farnesylpyrophosphate (FPP) to the cysteine residue of the carboxyl terminal CAAX tetrapeptide sequence (where C is a cysteine residue, A an aliphatic amino acid, and X either methionine or serine). In the endosome/Golgi membranes, transferase enzymes catalyze the removal of the AAX residues and the methylation of the resulting farnesyl-cysteine residue. A “second signal” is required to complete the translocation of Ras from endosomal membranes to the plasma membrane (Cox et al 2001).

The pathways that are controlled by activated Ras are designed to prolong cell survival and promote cell proliferation (Figure 4).

Figure 4 Simplified scheme of Ras activation. Ras proteins are activated by tyrosine kinase receptors as well as cytokine receptors. Once activated, GTP-bound Ras binds to effector molecules such as Raf kinase, Ral-GEF and PI3K. Ras signaling through Raf leads to sequential activation of MEK and ERK, resulting in cellular proliferation, differentiation and cell cycle progression. Ras activation of Ral-GEF causes activation of Rho, which induces stress fiber formation and actin polymerization/depolymerization. Activation of PI3K recruits PDK1/2 and AKT to the plasma membrane, resulting in activation of transcription factors, activation of glycogen synthetase, increased cell survival, and entry into the cell cycle by activating cyclin D1 (Morgan et al 2003).

One key pathway is the Raf-MEK-MAPK cascade. The Raf protein is a serine-threonine protein kinase that binds Ras to become active. Raf is able to initiate a downstream cascade of phosphorylation, ultimately resulting in the phosphorylation of mitogen-activated protein kinase (MAPK) also known as extracellular signal-regulated kinase (ERK), localized in the nucleus where it activates transcription factors involved in the control of cellular proliferation and apoptosis (Davies 1995; Bonni et al 1999). Transcription-independent mechanisms may also account for the pro-survival effect of this pathway via phosphorylation and subsequent inactivation of the proapoptotic BAD (Bcl-2-associated death promotor) protein. MAPK may be overexpressed or constitutively activated in hematopoietic malignancies, and may be a viable indirect target for FTIs.

The PI3K/AKT pathway occupies a critical position in the transduction of signals beginning with groth-stimulating cytokines and ending with cell proliferation and survival (Burgering and Coffer 1995; Klippel et al 1998). One trigger for this pathway is activated Ras, which interacts with PI3K in the phosphorylation and activation of the serine-threonine kinase AKT, which phosphorylates substrates involved in cell proliferation and survival following DNA damage or other cellular stresses. Vascular endothelial growth factor (VEGF), a pivotal growth and survival factor for leukemias, is also produced by the Ras-dependent AKT pathway (Mazure et al 1997). Other substrates, including those involved in cell cycle regulation and DNA repair, are inhibited as a result of AKT phosphorylation.

The Rho proteins are Ras-related GTP-binding proteins that coordinate growth factor-induced assembly of intracellular focal adhesions and actin stress fiber formation (Ridley and Hall 1992). Posttranslational prenylation occurs in these proteins, leading to both farnesylated and geranylgeranylated forms. The RhoB isoform is expressed at highest levels during the S-phase of the cell cycle. This small GTPase is involved in regulation of endosomal traffic (Ellis and Mellor 2000). FTI treatment leads to a shift toward geranylgeranylation of RhoB and altered cellular localization and function. As such, Rho may be a relevant target for FTI therapy. The geranylgeranylated form of RhoB accounts for up to 70% of the total RhoB protein in untreated cells. In the presence of FTIs, all of the cellular RhoB is geranylgeranylated (Lebowitz et al 1997). Inhibition of RhoB farnesylation may contribute to the antitumor activity of FTIs. Recently, it has been found that the geranylgeranylated form of RhoB inhibits expression from the cyclin B promotor and that under low serum conditions FTI treatment reduced cyclin B levels, leading to cell cycle arrest and apoptosis (Kamasani et al 2004).

Alternative targets

While it is becoming clear that FTIs only partly target Ras, how these agents selectively target leukemic cells has emerged as an important question. In the proteome, there are close to 300 proteins with a CAAX motif that are potentially farnesylated and over 20 proteins have been proven to be farnesylated (Kho et al 2004). Proteins that are not geranylgeranylated in FTI-treated cells are more likely to play a critical role in the biological response to FTIs.

CENP-E and CENP-F

CENP-E is a centromere-associated kinesin motor protein that functions in microtubule attachment to kinetochores, involved in the segregation of sister chromatids during mitosis. CENP-E is also essential for positioning chromosomes at the metaphase plate (Yao et al 1997). CENP-F is a cell cycle-regulated chromosome passenger protein that functions in mitosis (Liao et al 1995). FTIs may interfere with bipolar spindle formation during transition from prophase to metaphase in mitosis. Centromere proteins CENP-E and CENP-F are substrates for FTase but not geranylgeranyl transferase I (Ashar et al 2000). This mechanism contributes to the observed enhancement of antineoplasic activity of the combination of tipifarnib with antimicrotubule agents (Zhu et al 2005).

Rheb

Another potential target for FTI action include Rheb, a GTPase with two forms Rheb1 and Rheb2. Downstream from AKT in the signaling pathway, the target of rapamycin occupies a central position. AKT can inhibit the tuberous sclerosis TSC1/TSC2 (hamartin/tuberin) complex that turn off Rheb, which can activate the mamalian target of rapamycin/S6 kinase signaling (mTOR signaling). Rheb proteins are farnesylated. Rheb1 and Rheb2 are in vitro substrates for Ftase, but not GGTase-1, and treatment of cells with FTIs completely inhibits prenylation of Rheb. Activation of Rheb stimulates growth and cell cycle progression (Aspuria and Tamanoi 2004; Gau et al 2005). Inhibition of Rheb farnesylation may play a role in FTI enhancement of the antitumor response to other chemotherapeutics (Basso et al 2005). FTIs lead to a more complete of the Rheb signaling pathway than do mTOR/Raptor inhibitors such as rapamycin. FTIs inhibit signaling downstream of Rheb, including both mTOR/Raptor, which regulates growth, and mTOR/Rictor, which regulates the actin cytoskeleton.

RhoB

Rho proteins are involved in remodeling of actin cytoskeleton and in integrin-mediated cell adhesion: RhoA plays a role in the regulation of actomyosin contractility, RhoB regulates cytokine trafficking, and RhoC may be important in cell locomotion (Wheeler and Ridley 2004). RhoB can be prenylated. When farnesylation is blocked by FTIs, a shift of RhoB to RhoB geranylgeranylated occurs (Du and Prendergast 1999; Liu et al 2001). It has been suggested that the short half-life of RhoB corresponds to the rapid morphological reversion observed in some FTI-treated cells (Lebowitz et al 1997).

PTP-CAAX/PRL

The PTP-CAAX or PRL family of protein tyrosine phosphatases plays a role in regulating cell growth and mitosis. The PRL family includes three members, all of which are farnesylated proteins (Cates et al 1996). Cells ectopically expressing not prenylated PRL display defects in mitosis and cytokinesis characterized by chromosome bridges and lagging chromosomes. Farnesylated PRL is required for proper spindle dynamics. Inhibition of PRL farnesylation may in part account for FTI-induced accumulation of cells in the G2/M phase of the cell cycle (Wang et al 2002).

HDJ

Human DnaJ homologs include HDJ2, HSJ1, and HDJ1/Hsp40. These proteins serve as co-chaperones and stimulate the ATPase activity of Hsp70 (Nagata et al 1998). They increase the level of Hsp70 in its ADP-bound form that as greater affinity for unfolded polypeptide subtrates. This facilitates the folding of proteins and Hsp70-mediated nuclear trafficking. Although the functional significance of HDJ2 farnesylation remains unclear, HDJ2 prenylation status has been used as a marker for FTase inhibition in clinical trials. Studies suggest that farnesylation may regulate the activity, localization, or complex formation that is required for YDJ1 (the Saccharomyces cerevisiae homolog of HDJ2) function (Caplan et al 1992). There is little work reported to date on the functional consequences of blocking HDJ2 farnesylation in human cells.

Nuclear lamins

The nuclear lamina consists of lamin proteins that are required for nuclear envelope assembly. Lamin B was one of the first proteins shown to be modified by prenylation. Lamin A is also farnesylated. Although the functional role of lamin farnesylation remains unclear, it is though to play a role in targeting prelamin A to the nuclear membrane, where mature lamin A is released by the action of a protease (Sinensky et al 1994). The accumulation of unfarnesylated prelamin A can be detected and provides another marker for FTase inhibition. The functional role of lamin farnesylation remains unclear.

Additional farnesylated proteins

A number of other farnesylated proteins have been identified that may contribute to the biological activity of FTIs. These include other small GTPases: RhoD, RhoE, Rho6, Rho7, TC10, all of which have been demonstrated to be substrates for alternative prenylation by GGTase-1 (Basso et al 2006). Additional farnesylated proteins include the GTPase RRP22 and the prostacyclin receptor (Elam et al 2005).

Effects on cell cycle progression and on apoptosis

The inhibition of protein farnesylation interrupts the functions of diverse proteins that help to move the cell through its division cycle. FTIs may also impede the farnesylation and function of the kinetochore-binding centromeric proteins (CENPs) E and F, which exert their maximal effets in the G2 and M phases of the cell cycle (Ashar et al 2000). FTIs block the growth of a variety of leukemia cell lines both in vitro and when grown as xenografts in vivo. Tumor growth is inhibited by tipifarnib in these models over a dose range of 25–100 mg/kg twice daily (bid) (End et al 2001). FTIs induce G2/M accumulation and G1 arrest (Suzuki et al 1998) in both a p53-dependent and -independent fashion. FTIs are potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. This apoptotic response is blocked by BCL-X_L and inhibited by a myristylated form of RhoB (Lebowitz et al 1997b).

Preclinical and biological studies of tipifarnib in leukemia

The preclinical studies of FTI activities against a wide range of tumor cell types have demonstrated that the action of FTIs is not dependent upon the presence of ras mutations. In most preclinical models, FTIs induce tumor growth inhibition, when used as monotherapy (End et al 2001; Cox and Der 2002; Lancet and Karp 2003). Several genes involved in FTI biology were identified as being modulated following treatment with tipifarnib in addition to pathways involved with cytoskeletal organization, cell signaling, immunity, and apoptosis (Raponi et al 2004). Microarray analysis of pre-treatment bone marrow samples from patients with relapsed and refractory AML identified 8 genes that were associated with response to tipifarnib (Raponi et al 2007). The most robust marker was the guanine nucleotide exchange factor AKAP13, which showed increased expression in patients who were resistant to tipifarnib.

Clinical trials in acute myeloid leukemia

First trials in advanced cancer

Several single-agent phase I studies with tipifarnib have been reported. In an initial study, tipifarnib was dosed orally bid. for 5 days every two weeks. The maximum tolerated dose with this schedule was identified as 500 mg bid. Adverse events included nausea, vomiting, and fatigue. Myelosuppression was mild (Zujewski et al 2000). Another study explored a more prolonged schedule of 28 days of treatment followed by 1–2 weeks of rest. The maximum tolerated dose was 300 mg bid. and myelosuppression was dose-limiting (Punt et al 2001). A third study used tipifarnib at 300 mg bid. as continuous treatment. Myelosuppression and neurotoxicity were dose-limiting, but one partial response was observed (Crul et al 2002).

Phase I and phase II studies with tipifarnib as a single agent in AML

The most promising clinical results with tipifarnib have been observed in hematologic malignancies, including AML. In a phase I study of 35 adults with refractory or relapsed acute leukemia, 10 patients responded including 2 with complete responses. Patients were treated for 21 days, and dose limiting toxicities, including neurotoxicity, nausea and myelosuppression, were observed at the 1,200 mg bid. dose (Karp et al 2001). Responses were independent of ras mutational status. The optimal inhibition of protein farnesylation was obtained at 300 mg bid. for 21 days of a 28 day cycle (Zimmerman et al 2004). Clinical activity was confirmed in myelodysplastic syndromes (MDS), a pre-leukemic disease. In 21 patients with MDS, tipifarnib given at 300 mg bid. (3 weeks on/1 week off) resulted in one complete response, 2 partial responses, and 3 hematologic improvements (Kurzrock et al 2003). Responses were also observed when using a 4 week on/2 week off schedule (Kurzrock et al 2004). Intermittent dosing (bid. on alternative weeks) has also been shown more effective, in that higher doses (600 mg) can be given without toxicities (Lara et al 2005). In the presence of poor risk features, including older age, unfavorable cytogenetics, antecedents of MDS, and properties of multidrug resistance, the likelihood of disease-free survival (DFS) at one year is less than 20% (Leith et al 1997; Lancet et al 2000). In a phase 2 study, 82 patients with poor-risk MDS received tipifarnib (300 mg twice daily) for the first 21 days of each 28-day cycle. Twenty-six patients (32%) responded and 37 (45%) had stable disease. The median response duration was 11.5 months, and the median time to progression was 12.4 months (Fenaux et al 2007).

In patients older than 75 years, survival was in the order of 3 to 4 months, clearly highlighting the need for novel therapies in this group of patients (Appelbaum et al 2006; Kantarjian et al 2006). Activity has been reported with single-agent tipifarnib in poor-risk AML patients (Lancet et al 2007). In this study, a majority of patients had antecedents of MDS. Complete remission was achieved in 22 patients (14%) and partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%. Achievement of CR appeared to impart a major survival benefit. The median of DFS was 7.3 months and the median survival of complete responders was 18 months (Table 1). Tipifarnib was relatively well tolerated. Drug-related nonhematologic serious adverse events were observed in 47% of cases. The more frequently encountered were infection, gastrointestinal disturbances, renal insufficiency, and skin rash. Neurologic toxicity was rare and non-disease-related early mortality rate was only 7%, that compares favorably with death rates observed with induction chemotherapy in the elderly. Furthermore, because tipifarnib was administered orally, the median number of days spent in the hospital was low. Adverse karyotype and poor performance status correlated negatively with survival. Inhibition of farnesylation of the surrogate protein HDJ-2 occurred in a large majority of cases. Baseline levels of phosphorylated mitogen-activated protein kinase and AKT did not correlate with clinical response.

Table 1 Studies of phase I and II with tipifarnib as a single agent in acute myeloid leukemia and myelodysplastic syndrome

Reference	Study	Dose	Diagnosis	Patientsa age	Response	Survivalb (median)
Karp et al 2001	Phase I	100–1200 mg × 2	AML, ALL, CML-BC	34 patients	10/34 (29%) AML: 8/25 (32%)
Kurzrock et al 2003	Phase I	300 mg × 2	RA, RAEB, RAEB-t, CMML	20 patients 66 (50–83)	6/20 (30%) CR: 1, PR: 2, Imp: 3
Kurzrock et al 2004	Phase II	600 mg × 2	RA, RAEB, RAEB-t	27 patients 66 (49–80)	3/27 (11%) CR: 2, PR: 1
Lancet et al 2007	Phase II	600 mg × 2	AML	158 patients 74 (34–85)	22/158 (14%) PR + Imp: 15 CR + PR + Imp: 23%	DFS (7.3 months) OS (18 months)
Harousseau et al 2007	Phase II	600 mg × 2	AML	252 patients 62 (18–85)	11/252 (4%) CR: 9, CRp: 2	OS (12 months)

a Evaluable patients.

b Survival in responders.

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML-CB, chronic myeloid leukemia in blast crisis; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; CR, complete remission; Crp, complete remission with incomplete platelet recovery; PR, partial remission; Imp, hematologic improvement.

Another large study assessed the efficacy of tipifarnib as single-agent but in refractory or relapsing AML (Harousseau et al 2007) and confirmed the antileukemic activity initially observed in the phase I setting (Karp et al 2001). In this study, only 11 of 252 patients (4%) achieved complete remission (9 patients) or complete remission with incomplete platelet recovery (2 patients). Nineteen patients (8%), including those who achieved complete remission, achieved a reduction in bone marrow blasts to less than 5%. Bone marrow blasts were reduced by 50% in an additional 8 patients (Harousseau et al 2007) (Table 1). Despite a disappointingly low response rate, it was especially interesting to note the observation of complete remissions in cases presenting unfavorable cytogenetics. Myelosuppression was the most common adverse event. No new side effects related to tipifarnib treatment were identified. Treatment-related mortality was lower than that associated with standard induction chemotherapy. Results from this study suggest the consideration of combining tipifarnib with other antileukemic therapies.

Preclinical work showed that farnesyltransferase remained inhibited for seven days after tipifarnib, suggesting an alternate week dosing schedule. In a phase I dose escalation trial in AML on a week on week off schedule, 30 patients were accrued (Kirschbaum et al 2006). It was showed that greater than two fold increase in tipifarnib dosing can be tolerated on this dosing schedule with enhanced efficacy. Similar results were observed in MDS (Kurzrock et al 2006).

A recent study has shown that the median overall survival of older patients treated with tipifarnib was in fact longer than that of patients treated with the combination of idarubicin with cytarabine or idarubicin with other agents (Estey et al 2006). Despite these initial encouraging results, in 2005 the Oncology Drugs Advisory Committee rejected the approval of tipifarnib for the treatment of elderly patients with newly diagnosed poor-risk AML, citing an insufficient complete response rate. The relatively low toxicity profile may allow for extended therapy to maintian disease control, quality of life, and survival, even if full response is not achieved. The phase III trial (R115777-AML-301 trial) comparing tipifarnib with best supportive care may provide the necessary confirmatory data for approval. Tipifarnib in maintenance therapy during minimal residual disease has also been explored (R115777-INT-21 trial). Oral tipifarnib (400 mg bid for 2/3 weeks) was begun after start of final consolidation cycle and given for up to 36 cycles to 36 adults with poor risk AML (Karp et al 2006). Tipifarnib was well tolerated. However, dose reductions for myelosupression occurred in 53% and 6% needed platelet transfusions. A total of 15 patients progressed while on tipifarnib at median of 6.5 months from complete remission. There was no negative impact on reinduction chemotherapy at relapse.

Tipifarnib combined with other agents in AML

Trials that combine tipifarnib with other agents, most particularly cytotoxics, are ongoing. Indeed, pre-clinical data suggest that tipifarnib may be synergistic with some chemotherapeutic agents. In a phase I/II study in 74 adults with previously untreated AML or high-risk MDS, tipifarnib (200 mg bid or 300 mg bid for 21 days every 28 days) was combined with idarubicin (12 mg/m²/day for 3 days) and cytarabine (1.5 mg/m²/day for 4 days) (Alvarez et al 2006). A high rate of response was observed in AML (77%; 65% achieved complete remission and 12% complete remission with incomplete platelet recovery), with, however, an increased incidence of diarrhea and hyperbilirubinemia. Response by cytogenetics was 86% for diploid, 76% for monosomy 5 or 7, and 68% for other abnormalities. Patients achieving complete remission received 5 courses of consolidation with idarubicin (8 mg/m²/day for 2 days), cytarabine (0.75 mg/m²/day for 3 days), and tipifarnib (300 mg bid for 14 days) every 4–6 weeks. Maintenance was with tipifarnib 300 mg bid for 21 days every 4–6 weeks for 6 months.

In another phase I trial tipifarnib was combined with oral etoposide (Karp et al 2006b). This was conducted in an attempt to increase complete remission rates in elderly AML patients aged more than 70. Both tipifarnib and etoposide were given with escalating doses (300 mg to 600 mg bid for tipifarnib, and 100 mg to 200 mg/day for 6 days for etoposide) and 14 versus 21 days of tipifarnib every 28–63 days. While 43% of patients required hospitalization during the first cycle for a median of 7 days, overall hospitalization rate for all cycles was 28%. Complete remission was achieved in 21% of cases and partial remission or hematologic improvement in 20%. All patients who achieved complete remission have done so within two cycles. The oral regimen was therefore tolerable and feasible on an outpatient basis, with the suggestion of improvement of response rates over tipifarnib alone. Direct comparisons with chemotherapy alone are warranted in randomized trials.

Conclusion

FTIs exhibit encouraging signs of clinical activity in patients with AML. However, standard response criteria, which have proven valuable in the clinical development of cytotoxic agents, cannot be applied to FTIs, as with other new classes of targeted signal transduction inhibitors. This suggests that aggressive disease may not be appropriate settings to explore activity of FTIs. Greater activity is anticipated in the maintenance setting. New settings in which single-agent FTI therapy should be investigated include previously untreated AML and minimal residual disease. AML patients who are older than age 60 experience extremely poor long-term outcomes. New targeted agents like the FTIs offer the potential of increased therapeutic index, an important consideration in older patients with AML. One asset of this class of agents for this patient population is a toxicity profile that is very acceptable. FTIs might be administered on a chronic dosing schedule, either alone or in combination with other pharmacologic compounds, with the aim of maintaining the underlying disease in a clinically controlled state. On another front, FTIs seem optimal as postremission therapy for AML in elderly patients or those with other poor-risk features. Although there are limited data to suggest synergistic or additive effects, the combination of FTIs with chemotherapy represents another avenue of exploration.

Based on promising preliminary evidence of tolerability, biologic activity, and clinical response in some patients with AML, further studies with tipifarnib (as with other agent in this class) are warranted. The challenge will be to define the use of these new agents – when in the course of disease they should be administered, and in what combinations with other therapies. In this setting, novel agents with nonoverlapping mechanisms of action are to be combined and represent a potential step toward increasing favorable results in AML. A related challenge remains identifying a sensitive sub-type of leukemia based on a specific genetic profile. A common set of genes that were regulated by tipifarnib have been found. Expression of these candidate genes might be used as surrogate markers of drug activity. In addition, recent work has identified genes that may be predictive of resistance or response to tipifarnib. While these markers need to be further validated, their identification represent an important advance in the ability to stratify patients based on their likelihood of response.